Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5668 combination study in MUC16-positive gynecologic malignancies
2022-501904-83-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of REGN5668, cemiplimab, fianlimab and ubamatamab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of dose-limiting toxicities, Incidence of treatment-emergent adverse events and 5 more. Planned start Oct 2023; status: authorised.
02
Drugs
REGN5668cemiplimabfianlimabubamatamab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)endometrial cancer (EC)
Beyond the preview
Go deeper on 2022-501904-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501904-83-00.